Dermatological lighting- Dynamic Phototherapy

DERMARIS has been specially designed to treat actinic keratosis (AK) using photodynamic therapy (PDT).

AK is a skin lesion developed by chronic & heavy exposure to the sun that can develop into skin cancer. Protoporphyrin IX (PpIX) is a molecule present in KA cells that multiplies under the effect of the precursor. Aminolevulinic acid methyl ester (MAL) and 5-aminolevulinic acid (5-ALA) are drugs that act as precursors in the treatment of PDT.

PDT is a medical technique aimed at destroying pre-cancerous tissue through the use of photosensitising substances combined with a light source.

This light source offers a constant intensity of 20,000 Lux and a large, homogeneous treatment surface (20 cm).

The DERMARIS irradiance spectrum covers all the absorption peaks of the molecule used to destroy pre-cancerous cells.

Benefits

DERMARIS has many benefits:

• Ease of use: the lighting is compact and space-saving, making it easy to install patients (less than 2 minutes). Turning off the light head is easy as you just have to tilt it upwards to turn it off

• Unrivalled patient comfort: the treatment is silent

• Long-term use: over 30,000 treatments possible with a treatment time of 2h00

• Durable lighting: DERMARIS has a service life of 60,000 hours and the possibility of using it as examination lighting. Furthermore, the lighting requires no consumables.

Clinical studies

DERMARIS has been used in clinical studies, and here’s what the results show: (studies carried out on 38 people)

Efficacy :

• 58% of patients were free of KA lesions 3 months after treatment

• 32% of patients required a second AWL-PDT treatment

• 10% of patients had one to four KA lesions after 2 treatment

Pain:

• 33 of 38 patients (87%) experienced no pain during treatment

• 5 patients (13%) rated their pain level as 1 on a scale of 10

Post-treatment:

Discomfort in the six days following treatment was rated as :

• Non-existent (34% of patients)

• Mild (63% of patients)